Long-term survival of patients with acute myeloid leukemia : Updated results from two trials evaluating postinduction chemotherapy
✍ Scribed by Clara D. Bloomfield; Geoffrey P. Herzig; Bruce A. Peterson; Steven N. Wolff
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 121 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
METHODS.
Minimum follow-up of 21.6 years for living patients was obtained for 26 patients who received weekly cytarabine and 6-thioguanine maintenance ther-2 University of Minnesota, Minneapolis, Minneapy after achieving complete remission (CR) in the UMMCC study. Minimum sota.
follow-up of 7.7 years was obtained on 87 patients treated with high dose cytarabine 3 Vanderbilt University, Nashville, Tennessee.
intensification in first remission in the NAMTG study. 4 For the North American Transplant Group.
RESULTS.
In the UMMCC study, the LFS rate was 28% and the overall survival rate was 15%. Nineteen percent of patients died in first CR at 1.3-12 years. Three patients remain alive in initial CR at ú20 years. In the NAMTG study, the LFS rate was 49% and the overall survival rate was 45%. A total of 38 patients (44%) remain alive in initial CR at a median of 11.4 years after diagnosis. An additional patient is alive in second CR at 8.6 years after diagnosis. In both studies, relapses after 3 years were relatively uncommon (11-12%). Presented at Leukemia Long-Term Survival:
CONCLUSIONS. Chemotherapy alone is curative in more than 40% of AML patients
Collaborative Task Force Review and Analysis, who achieve CR. Short-term, high dose cytarabine intensification appeared more Orlando, Florida, December 5, 1996.
efficacious, without increased toxicity, compared with low dose, prolonged cytara-Supported in part by the Coleman Leukemia bine-based maintenance. However, for patients who cannot receive intensification, Research Fund.
prolonged, low dose maintenance therapy is an acceptable alternative for achieving cure. A minimum follow-up of 3 years is a reasonable predictor of long-term The authors are indebted to Ms. Jane Gau, Ms.
survival and should be obtained in studies evaluating therapeutic outcome in cases Linda Regal, and Ms. Cynthia Shuma for assis